Hance Clarke1, Joseph Kay, Nicholas Mitsakakis, Joel Katz. 1. Department of Anesthesia and Pain Management, Toronto General Hospital, Acute Pain Research Unit, 200 Elizabeth Street, Eaton North 3EB 317, Toronto, ON, M5G 2C4, Canada. hance.clarke@utoronto.ca
Abstract
PURPOSE: Much remains unknown about the relationship between acute postoperative pain and the development of pathologic chronic postsurgical pain (CPSP). The purpose of this project was to identify the extent to which maximum pain scores on movement over the first two days after total hip arthroplasty predicted the presence of chronic pain 6 months later after controlling for potentially important covariates. METHODS:The sample comprised 82 of 114 patients who participated in a double-blinded randomized controlled trial in which all patients received acetaminophen 1 g p.o., celecoxib 400 mg p.o., and dexamethasone 8 mg i.v., 1-2 h preoperatively. In addition, patients received gabapentin (GBP) 600 mg (G2) or placebo (G1 and G3) 2 h prior to surgery [G1: placebo/placebo (n = 38); G2: GBP/placebo (n = 38); G3: placebo/GBP (n = 38)]. In the PACU, patients received gabapentin 600 mg (G3) or placebo (G1 and G2). Follow-up data from the 82 patients who were contacted by telephone 6 months postsurgery were used for the current study. RESULTS:Maximal movement-evoked pain intensity over the first two postoperative days (P = 0.38) failed to predict the presence of CPSP 6 months later after controlling for age (P = 0.09), treatment group (P = 0.91), and cumulative morphine consumption (P = 0.8) (multivariate logistic regression likelihood ratio test against the intercept only model P = 0.59). CONCLUSION: Neither maximum movement-evoked acute pain, nor any other factor measured, predicted the presence of CPSP at 6 months. Further research is needed to identify risk factors for CPSP after total hip arthroplasty.
RCT Entities:
PURPOSE: Much remains unknown about the relationship between acute postoperative pain and the development of pathologic chronic postsurgical pain (CPSP). The purpose of this project was to identify the extent to which maximum pain scores on movement over the first two days after total hip arthroplasty predicted the presence of chronic pain 6 months later after controlling for potentially important covariates. METHODS: The sample comprised 82 of 114 patients who participated in a double-blinded randomized controlled trial in which all patients received acetaminophen 1 g p.o., celecoxib 400 mg p.o., and dexamethasone 8 mg i.v., 1-2 h preoperatively. In addition, patients received gabapentin (GBP) 600 mg (G2) or placebo (G1 and G3) 2 h prior to surgery [G1: placebo/placebo (n = 38); G2: GBP/placebo (n = 38); G3: placebo/GBP (n = 38)]. In the PACU, patients received gabapentin 600 mg (G3) or placebo (G1 and G2). Follow-up data from the 82 patients who were contacted by telephone 6 months postsurgery were used for the current study. RESULTS: Maximal movement-evoked pain intensity over the first two postoperative days (P = 0.38) failed to predict the presence of CPSP 6 months later after controlling for age (P = 0.09), treatment group (P = 0.91), and cumulative morphine consumption (P = 0.8) (multivariate logistic regression likelihood ratio test against the intercept only model P = 0.59). CONCLUSION: Neither maximum movement-evoked acute pain, nor any other factor measured, predicted the presence of CPSP at 6 months. Further research is needed to identify risk factors for CPSP after total hip arthroplasty.
Authors: Marisol A Hanley; Mark P Jensen; Douglas G Smith; Dawn M Ehde; W Thomas Edwards; Lawrence R Robinson Journal: J Pain Date: 2006-09-01 Impact factor: 5.820
Authors: L Borly; I B Anderson; L Bardram; E Christensen; A Sehested; H Kehlet; P Matzen; J F Rehfeld; P Stage; D B Toftdahl; A Gernow; L Højgaard Journal: Scand J Gastroenterol Date: 1999-11 Impact factor: 2.423
Authors: Norman R Harden; Stephen Bruehl; Steven Stanos; Victoria Brander; Ok Yung Chung; Samuel Saltz; Angie Adams; David S Stulberg Journal: Pain Date: 2003-12 Impact factor: 6.961
Authors: Dennis C Turk; Robert H Dworkin; Dennis Revicki; Gale Harding; Laurie B Burke; David Cella; Charles S Cleeland; Penney Cowan; John T Farrar; Sharon Hertz; Mitchell B Max; Bob A Rappaport Journal: Pain Date: 2007-10-15 Impact factor: 6.961
Authors: Joachim Erlenwein; Martin Müller; Deborah Falla; Michael Przemeck; Michael Pfingsten; Stefan Budde; Michael Quintel; Frank Petzke Journal: J Pain Res Date: 2017-09-07 Impact factor: 3.133
Authors: D A J M Latijnhouwers; C H Martini; R G H H Nelissen; S H M Verdegaal; T P M Vliet Vlieland; M G J Gademan Journal: Rheumatol Int Date: 2022-02-26 Impact factor: 2.631
Authors: Daisy M N Hoofwijk; Audrey A A Fiddelers; Peter J Emans; Elbert A Joosten; Hans-Fritz Gramke; Marco A E Marcus; Wolfgang F F A Buhre Journal: Medicine (Baltimore) Date: 2015-11 Impact factor: 1.817